ALK and non-small cell lung carcinoma: One retrospective study for advanced NSCLC patients with at least one oncogenic driver alteration receiving ICI monotherapy found that the median progression‐free survival (PFS) was only 2.8 months, and the objective response rates by driver alteration were generally low except RET (6%) and ALK (0%).15